Last reviewed · How we verify
NCT03494400: ATTBC
Aerobic Training in Treatment for Breast Cancer
NA trial testing Aerobic Training Presential in Cancer of Breast in 6 participants. Completed in 30 November 2020.
23 June 2019
Quick facts
| Lead sponsor | Universidade Estadual Paulista Júlio de Mesquita Filho |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 1 July 2018 |
| Primary completion | 23 June 2019 |
| Estimated completion | 30 November 2020 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Aerobic Training Presential
- Aerobic Training Home-based
Conditions studied
- Cancer of Breast — all drugs for Cancer of Breast →
- Healthy — all drugs for Healthy →
Sponsor
Universidade Estadual Paulista Júlio de Mesquita Filho — full company profile →
Who can join
18 and older, female only, with Cancer of Breast or Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction. Treatment with hormone therapy reduced the likelihood of tumor recurrence and metastasis in the patient. However, it has adverse effects such as: loss of bone mineral density, increase in body weight, metabolic changes and, consequently, lower quality of life. Physical training has been used as a means of reducing these and other adverse effects, but there is no definite protocol on which training model is effective, especially in patients who only use Tamoxifen or Aromatase Inhibitor as an adjuvant therapy for treatment of breast cancer. Objective: To compare the effect of aerobic training on body composition, metabolic and inflammatory variables, physical activity level, sleep, anxiety, depression, body image, fatigue, strength, flexibility and quality of life of women undergoing breast cancer treatment use Tamoxifen and Aromatase Inhibitor and women without cancer. Method. The sample will be formed by women without cancer and under treatment with hormone therapy being accompanied by the public service for treatment of breast cancer of the city of Presidente Prudente. A 24-week notification in which the face-to-face training group will undergo aerobic training three times a week on interspersed days and the group accompanied at a distance will perform as a preferred activity under a distance supervision of professionals every 14 days of return to attend the UNESP for the adequacy of the analysis and selection of attendance to the proposed activities. Evaluations of the variables of interest at the baseline of the intervention will be performed after 12 weeks and soon after the intervention. The investigators will analyze: biomarkers (TNFα, LDL, HDL, VLDL, as well as in the lipid profile (triglycerides, total cholesterol and LDL fractions ), glycemia, insulin, anthropometric measurements, physical activity level, sleep, pain, anxiety, depression, body image, fatigue, strength, flexibility. Trainings will be performed within the target zone of maximum heart rate. Comparisons between groups at each time point will be performed using Student's T-test for independent samples. The comparisons of the variables of interest at the initial moment and after 12 and 24 weeks will be made through the multivariate analysis, where the group effects, time and interaction of both will be compared. All analyzes will be performed in SPSS software version 24.0 and significance of 5%.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of home-based aerobic training combined with food orientation on food consumption, daily physical activity and cardiorespiratory fitness among breast cancer survivors: six-month clinical trial.
Reis AD, Lima LS, Barros ÊADC, Bertoli J, et al · · 2021 · cited 1× · PMID 33978132 · DOI 10.1590/1516-3180.2020.0658.28012021
Verify or expand the search:
- PubMed search for NCT03494400
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer of Breast
Currently open trials in the same condition.
- NCT06928818 — Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea · recruiting
- NCT06471673 — A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer · Phase 1, PHASE2 · recruiting
- NCT06085313 — Cancer Pain Management Using a Web-based Intervention · NA · recruiting
- NCT02476786 — Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence · Phase 2 · recruiting
Other Universidade Estadual Paulista Júlio de Mesquita Filho trials
Trials by the same sponsor.
- NCT07131748 — Effect of Heated Water-Based Versus Land-Based Exercise Training on Hemodynamic Variables, Functional Capacity and Quali · NA · recruiting
- NCT07113444 — Acute Effect of Tai Chi Versus Moderate-Intensity Combined Exercise on Cardiovascular, Metabolic, and Cardiac Autonomic · NA · not yet recruiting
- NCT07131761 — Effect of Tai Chi Versus Moderate-intensity Combined Exercise Training on Cardiovascular Health and Physical Functional · NA · not yet recruiting
- NCT06405477 — EFFECTS OF L-ARGININE SUPPLEMENTATION ON THE RECOVERY OF CARDIORESPIRATORY PARAMETERS AFTER SUBMAXIMAL EXERCISE TEST · NA · recruiting
- NCT06248164 — Relationship of Lifestyle Habits and Health Characteristics of Parents and Children · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03494400 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidade Estadual Paulista Júlio de Mesquita Filho
- Last refreshed: 30 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03494400.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing